Current Practice in the Treatment of Epithelial and Melanocytic Tumours with Interferon-α2b: A Survey of Tertiary Eye Centres in Germany.

Gegenwärtige Vorgehensweise bei der Behandlung von epithelialen und melanozytären Tumoren mit Interferon-α2b: eine Umfrage unter tertiären Augenzentren in Deutschland.

Journal

Klinische Monatsblatter fur Augenheilkunde
ISSN: 1439-3999
Titre abrégé: Klin Monbl Augenheilkd
Pays: Germany
ID NLM: 0014133

Informations de publication

Date de publication:
Jul 2023
Historique:
medline: 21 7 2023
pubmed: 7 2 2023
entrez: 6 2 2023
Statut: ppublish

Résumé

To evaluate the standard of care, in particular the use of topical or subconjunctival interferon- A survey containing 14 questions was sent to 43 tertiary eye centres in Germany. The questions addressed the surgical and medical management of ocular surface squamous neoplasia and melanocytic tumours (primary acquired melanosis and malignant melanoma), as well as the clinical experiences and difficulties in prescribing off-label interferon- Twenty-four tertiary eye centres responded to the survey. Eighty-three percent of centres had used interferon- Off-label mitomycin C was the preferred adjuvant therapy for epithelial and melanocytic tumours, with interferon- ZIEL: Evaluation des Therapiestandards, insbesondere der Verwendung von topischem oder subkonjunktivalem Interferon- Eine Umfrage mit 14 Fragen wurde an 43 tertiäre Augenzentren in Deutschland verschickt. Die Fragen befassten sich mit der chirurgischen und medizinischen Behandlung von Neoplasien der plattenepithelialen, okulären Oberfläche und melanozytären Tumoren (primär erworbene Melanose und malignes Melanom) sowie den klinischen Erfahrungen und Schwierigkeiten bei der Verschreibung von Off-Label Interferon- 24 tertiäre Augenzentren nahmen an der Umfrage teil. 83% der Zentren hatten Interferon- Off-Label Mitomycin C war die bevorzugte adjuvante Therapie für epitheliale und melanozytäre Tumoren, während Interferon-

Autres résumés

Type: Publisher (ger)
ZIEL: Evaluation des Therapiestandards, insbesondere der Verwendung von topischem oder subkonjunktivalem Interferon-

Identifiants

pubmed: 36746398
doi: 10.1055/a-2029-0163
doi:

Substances chimiques

Interferon-alpha2b 0
Mitomycin 50SG953SK6
Interferon-alpha 0
Ophthalmic Solutions 0
Recombinant Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

891-896

Informations de copyright

Thieme. All rights reserved.

Déclaration de conflit d'intérêts

The authors declare that they have no conflict of interest. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Auteurs

Jana Jiang (J)

Eye Center, University Medical Center Freiburg, Germany.

Daniel Böhringer (D)

Eye Center, University Medical Center Freiburg, Germany.

Claudia Auw-Hädrich (C)

Eye Center, University Medical Center Freiburg, Germany.

Philip Christian Maier (PC)

Eye Center, University Medical Center Freiburg, Germany.

Teresa Barth (T)

Department of Ophthalmology, University Hospital Regensburg, Germany.

Nicole Eter (N)

Department of Ophthalmology, University of Münster Medical Center, Germany.

Matthias Fuest (M)

Department of Ophthalmology, RWTH Aachen University, Germany.

Gerd Geerling (G)

Department of Ophthalmology, University Hospital, University of Düsseldorf, Germany.

Ludwig M Heindl (LM)

Department of Ophthalmology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Germany.

Martina Herwig-Carl (M)

Department of Ophthalmology, University of Bonn, Germany.

Christoph Hintschich (C)

Department of Oculoplastic and Orbital Service, Munich University Eye Hospital, Germany.

Katerina Hufendiek (K)

University Eye Hospital, Hannover Medical School, Germany.

Daniel Kampik (D)

Department of Ophthalmology, University Hospital of Würzburg, Germany.

Wolfgang Lieb (W)

Department of Ophthalmology, St. Vincentius Clinic Karlsruhe, Germany.

Daniel Meller (D)

Department of Ophthalmology, Jena University Hospital, Germany.

Arthur Mueller (A)

Department of Ophthalmology, University Hospital Augsburg, Germany.

Norbert Pfeiffer (N)

Department of Ophthalmology, University Medical Center of the Johannes Gutenberg-University Mainz, Germany.

Matus Rehak (M)

Department of Ophthalmology, Eye Clinic, Justus-Liebig-University Giessen, University Hospital Giessen and Marburg GmbH, Germany.

Marc Schargus (M)

Department of Ophthalmology, Asklepios Hospital Nord-Heidberg, Hamburg, Germany.

Berthold Seitz (B)

Department of Ophthalmology, Saarland University Medical Center, Homburg, Germany.

Martin Spitzer (M)

Clinic for Ophthalmology, University Medical Center Hamburg-Eppendorf (UKE), Germany.

Andreas Stahl (A)

Department of Ophthalmology, University Medicine Greifswald, Germany.

Daniela Süsskind (D)

Department of Ophthalmology, Eberhard Karls Universität, Tübingen, Germany.

Christian van Oterendorp (C)

Department of Ophthalmology, Georg-August University, Göttingen, Germany.

Felix Mathias Wagner (FM)

Ophthalmology Department, Philipps University of Marburg, Germany.

Henrike Westekemper (H)

Department of Ophthalmology, University Hospital Essen, Germany.

Focke Ziemssen (F)

Department of Ophthalmology, University Hospital Leipzig, Germany.

Thomas Reinhard (T)

Eye Center, University Medical Center Freiburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH